摘要
目的对肝癌患者给予艾迪注射液联合HLF化疗方案治疗,探究和分析其临床效果。方法选择该院肝癌患者为研究对象,时间为2015年1月—2017年12月,共计60例,按照随机数字法分配原则分为对照组和观察组,每组30例,对照组给予常规化疗NP方案治疗,观察组给予艾迪注射液联合HLF化疗方案治疗,两组治疗4周为一周期,重复治疗4个周期。比较两组患者症状改善,毒副反应以及生活质量情况。结果观察组治疗改善率为50.00%,对照组治疗改善率为36.67%。两组比较差异有统计学意义(χ~2=5.925,P=0.042);对照组18例出现胃肠道反应,发生率为60.00%,观察组10例出现胃肠道反应,发生率为33.33%。两组比较差异有统计学意义(χ~2=5.146,P=0.037)。对照组病例患者生活质量改善率43.33%,而观察组的生活质量改善率为73.33%。观察组生活质量改善率优于对照组(χ~2=6.972,P=0.035)。结论艾迪注射液液联合HLF化疗方案治疗肝癌,能够调节减轻毒副反应,提升患者治疗后的生活质量,提升近期疗效。
Objective To treat the liver cancer patients with Aidi injection combined with HLF chemotherapy, and to explore and analyze its clinical effects. Methods The patients with liver cancer in the hospital were selected as subjects. The time was from January 2015 to December 2017. A total of 60 patients were divided into the control group and the observation group according to the principle of random number distribution. 30 patients in each group were given conventional chemotherapy and the NP regimen was treated. The observation group was treated with Aidi injection combined with HLF chemotherapy. The two groups were treated for 4 weeks and re-peated for four cycles. Symptom improvement, toxicity, and quality of life were compared between the two groups. Results The im-provement rate of treatment in the observation group was 50.00%, and the improvement rate in the control group was 36.67%. The difference between the two groups was significant（χ^2=5.925, P=0.042）; the gastrointestinal reaction occurred in 18 patients in the control group, the incidence rate was 60.00%, and the gastrointestinal reaction occurred in 10 patients in the observation group, the incidence rate was 33.33%. The difference between the two groups was significant and statistically significant（ χ^2=5.146, P=0.037）.The quality of life improvement rate of the patients in the control group was 43.33%, while the improvement rate of quality of life in the observation group was 73.33%. The improvement rate of quality of life in the observation group was better than that in the control group（χ^2=6.972, P=0.035）. Conclusion Aidi injection combined with HLF chemotherapy for liver cancer can regulate the reduction of toxic and side effects, improve the quality of life of patients after treatment, and improve the short-term efficacy.
作者
杨斌峰
YANG Bin-feng(Department of Oncology,the First People＇s Hospital of Wujiang District,Suzhou,.liangsu Province,215200 China)
出处
《世界复合医学》
2018年第3期51-53,共3页
World Journal of Complex Medicine
关键词
艾迪注射液
HLF化疗
肝癌
临床疗效
Aidi injection
HLF chemotherapy
Liver cancer
Clinical efficacy
